Cumulative social disadvantage and health-related quality of life: national health interview survey 2013-2017.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
04 09 2023
Historique:
received: 06 09 2022
accepted: 21 06 2023
medline: 6 9 2023
pubmed: 5 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

Evidence for the association between social determinants of health (SDoH) and health-related quality of life (HRQoL) is largely based on single SDoH measures, with limited evaluation of cumulative social disadvantage. We examined the association between cumulative social disadvantage and the Health and Activity Limitation Index (HALex). Using adult data from the National Health Interview Survey (2013-2017), we created a cumulative disadvantage index by aggregating 47 deprivations across 6 SDoH domains. Respondents were ranked using cumulative SDoH index quartiles (SDoH-Q1 to Q4), with higher quartile groups being more disadvantaged. We used two-part models for continuous HALex scores and logistic regression for poor HALex (< 20th percentile score) to examine HALex differences associated with cumulative disadvantage. Lower HALex scores implied poorer HRQoL performance. The study sample included 156,182 respondents, representing 232.8 million adults in the United States (mean age 46 years; 51.7% women). The mean HALex score was 0.85 and 17.7% had poor HALex. Higher SDoH quartile groups had poorer HALex performance (lower scores and increased prevalence of poor HALex). A unit increase in SDoH index was associated with - 0.010 (95% CI [-0.011, -0.010]) difference in HALex score and 20% higher odds of poor HALex (odds ratio, OR = 1.20; 95% CI [1.19, 1.21]). Relative to SDoH-Q1, SDoH-Q4 was associated with HALex score difference of -0.086 (95% CI [-0.089, -0.083]) and OR = 5.32 (95% CI [4.97, 5.70]) for poor HALex. Despite a higher burden of cumulative social disadvantage, Hispanics had a weaker SDoH-HALex association than their non-Hispanic White counterparts. Cumulative social disadvantage was associated with poorer HALex performance in an incremental fashion. Innovations to incorporate SDoH-screening tools into clinical decision systems must continue in order to accurately identify socially vulnerable groups in need of both clinical risk mitigation and social support. To maximize health returns, policies can be tailored through community partnerships to address systemic barriers that exist within distinct sociodemographic groups, as well as demographic differences in health perception and healthcare experience.

Sections du résumé

BACKGROUND
Evidence for the association between social determinants of health (SDoH) and health-related quality of life (HRQoL) is largely based on single SDoH measures, with limited evaluation of cumulative social disadvantage. We examined the association between cumulative social disadvantage and the Health and Activity Limitation Index (HALex).
METHODS
Using adult data from the National Health Interview Survey (2013-2017), we created a cumulative disadvantage index by aggregating 47 deprivations across 6 SDoH domains. Respondents were ranked using cumulative SDoH index quartiles (SDoH-Q1 to Q4), with higher quartile groups being more disadvantaged. We used two-part models for continuous HALex scores and logistic regression for poor HALex (< 20th percentile score) to examine HALex differences associated with cumulative disadvantage. Lower HALex scores implied poorer HRQoL performance.
RESULTS
The study sample included 156,182 respondents, representing 232.8 million adults in the United States (mean age 46 years; 51.7% women). The mean HALex score was 0.85 and 17.7% had poor HALex. Higher SDoH quartile groups had poorer HALex performance (lower scores and increased prevalence of poor HALex). A unit increase in SDoH index was associated with - 0.010 (95% CI [-0.011, -0.010]) difference in HALex score and 20% higher odds of poor HALex (odds ratio, OR = 1.20; 95% CI [1.19, 1.21]). Relative to SDoH-Q1, SDoH-Q4 was associated with HALex score difference of -0.086 (95% CI [-0.089, -0.083]) and OR = 5.32 (95% CI [4.97, 5.70]) for poor HALex. Despite a higher burden of cumulative social disadvantage, Hispanics had a weaker SDoH-HALex association than their non-Hispanic White counterparts.
CONCLUSIONS
Cumulative social disadvantage was associated with poorer HALex performance in an incremental fashion. Innovations to incorporate SDoH-screening tools into clinical decision systems must continue in order to accurately identify socially vulnerable groups in need of both clinical risk mitigation and social support. To maximize health returns, policies can be tailored through community partnerships to address systemic barriers that exist within distinct sociodemographic groups, as well as demographic differences in health perception and healthcare experience.

Identifiants

pubmed: 37667245
doi: 10.1186/s12889-023-16168-8
pii: 10.1186/s12889-023-16168-8
pmc: PMC10476290
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1710

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Annu Rev Public Health. 2011;32:381-98
pubmed: 21091195
Front Nutr. 2018 Oct 25;5:99
pubmed: 30410883
J Gerontol B Psychol Sci Soc Sci. 1995 Nov;50(6):S344-53
pubmed: 7583813
Qual Life Res. 1998 Feb;7(2):101-14
pubmed: 9523491
J Gen Intern Med. 2005 Oct;20(10):911-5
pubmed: 16191137
Am J Public Health. 2003 Aug;93(8):1335-41
pubmed: 12893624
Prev Chronic Dis. 2015 Sep 24;12:E162
pubmed: 26402052
J Adolesc Health. 2022 Jun;70(6):928-933
pubmed: 35165033
Med Decis Making. 2010 Jan-Feb;30(1):5-15
pubmed: 19843961
BMC Public Health. 2012 Jan 10;12:19
pubmed: 22233446
Mayo Clin Proc. 2022 Feb;97(2):238-249
pubmed: 35120692
Soc Sci Med. 2012 Jul;75(1):1-9
pubmed: 22265085
Hypertension. 2022 Jan;79(1):196-206
pubmed: 34784734
Med Care. 2014 Dec;52(12):1010-6
pubmed: 25014733
BMC Cardiovasc Disord. 2020 Feb 11;20(1):76
pubmed: 32046641
Value Health. 2016 Sep - Oct;19(6):704-719
pubmed: 27712695
Int J Equity Health. 2017 Jun 6;16(1):94
pubmed: 28587654
Psychol Bull. 2020 Nov;146(11):970-1020
pubmed: 33090862
Soc Sci Med. 2005 Jan;60(1):191-204
pubmed: 15482878
BMC Public Health. 2013 Apr 09;13:320
pubmed: 23570559
PeerJ. 2016 Sep 22;4:e2508
pubmed: 27688982
Qual Life Res. 2008 Nov;17(9):1125-35
pubmed: 18836850
Soc Sci Med. 2009 Aug;69(3):307-16
pubmed: 19520474
Int J Health Policy Manag. 2017 Aug 05;7(1):1-9
pubmed: 29325397
Med Decis Making. 2016 Oct;36(7):900-10
pubmed: 26785714
Annu Rev Public Health. 2022 Apr 5;43:355-373
pubmed: 34882431
Gerontologist. 2018 Jan 18;58(1):4-14
pubmed: 29029195
Eur Heart J. 2014 Aug 7;35(30):2001-9
pubmed: 24904027
Am J Prev Cardiol. 2021 Aug 30;8:100251
pubmed: 34553187
J Am Geriatr Soc. 2020 Aug;68(8):1731-1738
pubmed: 32227645
J Gen Intern Med. 2015 Oct;30(10):1383-4
pubmed: 26224154
JAMA Cardiol. 2021 Aug 1;6(8):880-888
pubmed: 34009238
Qual Life Res. 2021 Mar;30(3):881-889
pubmed: 33161483
Rev Esc Enferm USP. 2022 May 27;56:e20210482
pubmed: 35635791
Respiration. 2011;82(5):402-8
pubmed: 21778694
Psychooncology. 2022 Nov;31(11):1922-1932
pubmed: 35953894
Lancet. 2012 Sep 15;380(9846):1011-29
pubmed: 22964159
Qual Life Res. 2011 Sep;20(7):1131-40
pubmed: 21298347
Am J Public Health. 2012 May;102(5):836-43
pubmed: 22493998
Lancet Public Health. 2021 Mar;6(3):e145-e154
pubmed: 33516278
Obesity (Silver Spring). 2022 Feb;30(2):491-502
pubmed: 35088551
J Gerontol A Biol Sci Med Sci. 2021 Mar 31;76(4):735-740
pubmed: 33049033
Lancet. 2008 Nov 8;372(9650):1661-9
pubmed: 18994664
J Pers. 2009 Dec;77(6):1707-46
pubmed: 19796063
JAMA. 2020 Apr 28;323(16):1553-1554
pubmed: 32242887
J Am Heart Assoc. 2023 Mar 21;12(6):e025581
pubmed: 36926956
J Am Med Inform Assoc. 2020 Nov 1;27(11):1764-1773
pubmed: 33202021
J Racial Ethn Health Disparities. 2022 Apr;9(2):462-477
pubmed: 33544329
Perspect Health Inf Manag. 2022 Mar 15;19(Spring):1g
pubmed: 35692849
Health Qual Life Outcomes. 2021 Sep 22;19(1):221
pubmed: 34551778

Auteurs

Kobina Hagan (K)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.

Zulqarnain Javed (Z)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.

Miguel Cainzos-Achirica (M)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.
Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, 77030, Houston, TX, USA.

Adnan A Hyder (AA)

Center on Commercial Determinants of Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.

Elias Mossialos (E)

Department of Health Policy, London School of Economics and Political Sciences, London, UK.
Centre for Health Policy, Imperial College London, London, UK.

Tamer Yahya (T)

Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, 77030, Houston, TX, USA.

Isaac Acquah (I)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.

Javier Valero-Elizondo (J)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.

Alan Pan (A)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.

Nwabunie Nwana (N)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA.

Mohamad Taha (M)

Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, 77030, Houston, TX, USA.

Khurram Nasir (K)

Division of Health Equity and Health Disparities Research, Center for Outcomes Research, Houston Methodist, Houston, TX, USA. knasir@houstonmethodist.org.
Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, 6550 Fannin St Suite 1801, 77030, Houston, TX, USA. knasir@houstonmethodist.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH